GHRS · NASDAQ · Biotechnology

GH Research (GHRS)

Develops mebufotenin therapies and delivery systems for treatment-resistant depression.

$27.86
After-hours close−0.05 (−0.18%)
At close$27.91(−0.07%)

Something off on this page? Send us feedback.

Next report
Nov 5, 26
estimated · in 44 days
EPS estimate
−$0.27
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.17−$0.19−$0.15−$0.23−$0.23−$0.31−$0.23Pending
Estimate−$0.23−$0.61−$0.22−$0.23−$0.29−$0.27−$0.29−$0.27
Surprise+26.1%+68.9%+31.8%0.0%+20.7%−14.8%+19.6%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2027−$0.43
Sep 2027−$0.41
Jun 2027−$0.34
Mar 2027−$0.34
Dec 2026−$0.36
Nov 2026−$0.27
Aug 2026−$0.29−$0.23+19.6%
May 2026−$0.27−$0.31−14.8%
Mar 2026−$0.29−$0.23+20.7%
Nov 2025−$0.23−$0.230.0%
Aug 2025
May 2025
Feb 2025
Nov 2024
Sep 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2027−$0.43$0
Sep 2027−$0.41$0
Jun 2027−$0.34$0
Mar 2027−$0.34$0
Dec 2026−$0.36$0
Nov 5, 2026−$0.27$0
Aug 6, 2026−$0.29−$0.23+19.6%+5.2%
May 14, 2026−$0.27−$0.31−14.8%+1.5%
Mar 5, 2026−$0.29−$0.23+20.7%−5.1%
Nov 6, 2025−$0.23−$0.230.0%−1.3%
Aug 7, 2025
May 8, 2025
Feb 27, 2025
Nov 14, 2024
Sep 3, 2024
May 3, 2024
Feb 29, 2024
Nov 9, 2023
Aug 23, 2023
May 11, 2023
Mar 2, 2023
Nov 10, 2022
Aug 23, 2022
May 18, 2022
Mar 28, 2022
Dec 6, 2021
Sep 23, 2021
Jun 28, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.